Aligos Therapeutics, Inc.
ALGS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $37 | $136 | $81 | $187 |
| Short-Term Investments | $20 | $0 | $44 | $4 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $5 | $8 | $14 |
| Total Curr. Assets | $62 | $141 | $134 | $204 |
| Property Plant & Equip (Net) | $7 | $10 | $13 | $15 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $15 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $8 | $10 | $13 | $31 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $70 | $152 | $147 | $235 |
| Liabilities | – | – | – | – |
| Payables | $3 | $3 | $5 | $3 |
| Short-Term Debt | $3 | $3 | $3 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $1 | $9 | $8 |
| Other Curr. Liab. | $16 | $17 | $16 | $25 |
| Total Curr. Liab. | $22 | $24 | $33 | $39 |
| LT Debt | $5 | $8 | $9 | $12 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $2 | $0 | $0 | $0 |
| Other NC Liab. | $72 | $28 | $0 | $0 |
| Total NC Liab. | $79 | $36 | $10 | $12 |
| Other Liabilities | -$2 | $0 | $0 | $0 |
| Cap. Leases | $8 | $11 | $13 | $14 |
| Total Liabilities | $99 | $59 | $43 | $51 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$618 | -$487 | -$399 | -$303 |
| AOCI | $0 | $1 | $0 | $0 |
| Other Equity | $589 | $578 | $503 | $487 |
| Total Equity | -$29 | $92 | $104 | $185 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $70 | $152 | $147 | $235 |
| Net Debt | -$29 | -$125 | -$69 | -$172 |